Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis

Arthritis Rheum. 2006 Apr 15;55(2):333-7. doi: 10.1002/art.21841.

Authors

Jon T Giles¹, Susan J Bartlett, Allan C Gelber, Shikha Nanda, Kevin Fontaine, Victoria Ruffing, Joan M Bathon

Affiliation

¹ The Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Suite 1B.1, Baltimore, MD 21224, USA. gilesjont@jhmi.edu

PMID: 16583385
DOI: 10.1002/art.21841

No abstract available

MeSH terms

Adalimumab
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / adverse effects*
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / surgery*
Bacterial Infections / etiology*
Etanercept
Female
Humans
Immunoglobulin G / adverse effects*
Infliximab
Male
Middle Aged
Orthopedic Procedures
Postoperative Complications / etiology*
Receptors, Tumor Necrosis Factor
Risk Factors
Severity of Illness Index
Tumor Necrosis Factor Inhibitors*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor Inhibitors
Infliximab
Adalimumab
Etanercept